Filice, E
Triple Agonists (GLP-1/GIP/Glucagon) Drug-Drug Interaction Table At a glance Prototype drug / retatrutide (LY3437943) Mechanism / simultaneous GLP-1R, GIPR, and glucagon receptor agonism Phase 2 weight loss (48 wk) / 24.2% mean body weight reduction vs 2.1% placebo Primary metabolic targets / obesity, MASLD/MASH, T2D, dyslipidemia Gastric emptying effect / marked slowing, peak drug interaction risk 1 to 4 h post-dose Oral drug most affected / warfarin, oral contraceptives, levothyroxine, cyclosporine Hypoglycemia risk / low monotherapy
Upgrade Your Services : Elevate your beauty salon, day spa, or skin clinic with this innovative product
Each photo should include the FormBlends label and a caption noting the date the photo was taken (so we can track formulation changes over time)
While these injections have been approved for long-term use, theyre not meant to be a solution for weight loss on their own
Your healthcare provider will manage the injection site and all related procedures, such as rotating injection sites, to ensure safety and minimize the risk of skin irritation